REP 2139-Mg在HDV相关晚期肝病同情用药项目中的安全性与疗效
国际同情用药项目纳入33例HDV相关晚期慢性肝病患者,每周皮下注射REP 2139-Mg 250 mg联合核苷酸类似物,20例加用聚乙二醇干扰素。治疗结束时70%患者HDV RNA下降>2 log10,58%转阴,27%实现HBsAg清除;随访28例中46%HDV RNA持续阴性、18%HBsAg持续阴性,未观察到REP相关严重不良事件。
要点
- REP 2139-Mg联合核苷酸类似物可使多数HDV晚期肝病患者HDV RNA显著下降或转阴。
- 治疗结束HBsAg清除率27%,随访1年18%维持HBsAg不可测,提示HBV功能治愈可能。
- 疗效与是否联用聚乙二醇干扰素相似,且未观察到REP相关严重不良事件。
核心结论
- REP 2139-Mg在HDV相关晚期慢性肝病患者中安全有效,可能诱导HDV持续病毒学应答和HBV功能治愈,且不依赖聚乙二醇干扰素联用。
研究设计与样本
- 国际同情用药项目(NCT05683548)纳入33例HDV相关晚期慢性肝病患者,每周皮下注射REP 2139-Mg 250 mg联合核苷酸类似物,计划疗程48周。
- 20例无禁忌证患者加用聚乙二醇干扰素α 45-180 μg每周;定期评估安全性和疗效,并对1例肝移植标本进行肝内标志物检测。
主要发现
- 33例患者年龄21-69岁,男性21例;85%(28/33)既往治疗失败,6例为失代偿期肝硬化(其中5例腹水)。
- 21例因应答欠佳接受剂量调整(250 mg静脉或500 mg皮下/静脉)和/或疗程延长。
- 治疗结束时HDV RNA下降>2 log10者占70%(23/33),不可测者占58%(19/33);HBsAg清除者占27%(9/33)。
- 28例有随访资料者中,HDV RNA和HBsAg持续不可测分别占46%(13/28)和18%(5/28);ALT复常占50%(14/28)。
- 5例腹水患者中2例改善;3例在REP治疗期间接受肝移植无并发症;1例肝移植标本HDV RNA和HDAg不可测,肝内cccDNA活性和HBsAg水平极低。
关键数值与推荐
- HDV RNA下降>2 log10:70%(23/33);HDV RNA不可测:58%(19/33);HBsAg清除:27%(9/33)。
- 随访中HDV RNA持续不可测:46%(13/28);HBsAg持续不可测:18%(5/28);ALT复常:50%(14/28)。
- 联用或不联用聚乙二醇干扰素应答相似;未观察到REP相关严重不良事件。
临床怎么用
- 对于HDV相关晚期慢性肝病且既往治疗失败或无获批治疗选择的患者,REP 2139-Mg联合核苷酸类似物可能带来病毒学和生化应答。
- 治疗中可根据应答进行剂量调整或延长疗程,失代偿期肝硬化患者也可能观察到临床改善。
- 该方案安全性可接受,但需在正规临床研究或同情用药框架下使用并密切监测。
局限性
- 为同情用药项目,非随机对照试验,样本量较小(33例),随访数据仅28例可用。
- 肝内标志物仅来自1例肝移植标本,代表性有限。
- 疗效与安全性需在应答指导的临床试验中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: REP 2139-Mg (REP), a nucleic acid polymer, blocks HBV subviral particle assembly and HDV replication. We report the outcomes of REP treatment in patients with HDV enrolled in a compassionate access program (NCT05683548). METHODS: Thirty-three patients with HDV and advanced chronic liver disease received weekly subcutaneous REP 250 mg plus a nucleotide analogue for a planned 48-week treatment course. Pegylated interferon-α (PegIFN) 45-180 μg weekly was added in 20 patients without contraindications. Safety and efficacy were assessed regularly, and intrahepatic markers were evaluated in one liver explant. RESULTS: Among the 33 patients (age 21-69 years; 21 males), 85% (28/33) had prior treatment failure, and six had decompensated cirrhosis (ascites in five). Suboptimal responses to REP were managed with dose modifications (250 mg intravenously or 500 mg subcutaneously or intravenously) and/or treatment extension in 21 patients. At end of therapy, HDV RNA declined by >2 log10 in 70% (23/33) and became undetectable in 58% (19/33). HBsAg loss occurred in 27% (9/33). Among the 28 patients with available follow-up, HDV RNA and HBsAg remained undetectable in 46% (13/28) and 18% (5/28), respectively. ALT normalized in 50% (14/28). Responses were similar with or without PegIFN. Ascites improved in two of five affected patients. Three patients underwent liver transplantation while receiving REP without complications. In one liver explant, HDV RNA and HDAg were undetectable, and intrahepatic covalently closed circular DNA activity and HBsAg levels were very low. No REP-related serious adverse events were observed. CONCLUSIONS: REP treatment was safe and effective in patients with HDV and advanced chronic liver disease. REP may induce sustained virological response of HDV and functional cure of HBV, independent of PegIFN co-administration. Clinical improvement may also occur in patients with decompensated cirrhosis. IMPACT AND IMPLICATIONS: No approved antiviral therapy exists for patients with chronic hepatitis D (CHD) and decompensated cirrhosis, or for those who have failed bulevirtide and/or pegylated interferon. In the Replicor Compassionate Access Program, 33 patients with CHD and advanced chronic liver disease received REP 2139-Mg (REP) plus a nucleotide analogue, with or without pegylated interferon. HBsAg loss occurred in 27% at end of treatment and remained undetectable in 18% after 1 year, indicating sustained HDV virological response and HBV functional cure. Among six patients with decompensated cirrhosis, five achieved a virological response and two showed clinical improvement with reduced ascites. No REP-related serious adverse events were observed. Overall, REP demonstrated promising efficacy and acceptable tolerability in this difficult-to-treat population and warrants evaluation in a response-guided clinical trial.
引用
- Stern C, Loustaud-Ratti V, Yurdaydin C, et al. Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program. J Hepatol. 2025. PMID: 41205755. doi:10.1016/j.jhep.2025.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。